JP2019068857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019068857A5 JP2019068857A5 JP2019019707A JP2019019707A JP2019068857A5 JP 2019068857 A5 JP2019068857 A5 JP 2019068857A5 JP 2019019707 A JP2019019707 A JP 2019019707A JP 2019019707 A JP2019019707 A JP 2019019707A JP 2019068857 A5 JP2019068857 A5 JP 2019068857A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- microglobulin
- acid sequence
- nucleic acid
- human animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 29
- 150000007523 nucleic acids Chemical group 0.000 claims 29
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 19
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 16
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 101000937526 Mus musculus Beta-2-microglobulin Proteins 0.000 claims 8
- 102000047279 human B2M Human genes 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000001105 regulatory effect Effects 0.000 claims 6
- 108700024394 Exon Proteins 0.000 claims 4
- 241000283984 Rodentia Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 101000729860 Rattus norvegicus Beta-2-microglobulin Proteins 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552587P | 2011-10-28 | 2011-10-28 | |
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US61/552,587 | 2011-10-28 | ||
| US61/552,582 | 2011-10-28 | ||
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| US61/700,908 | 2012-09-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017109327A Division JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081774A Division JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019068857A JP2019068857A (ja) | 2019-05-09 |
| JP2019068857A5 true JP2019068857A5 (cg-RX-API-DMAC10.html) | 2019-12-19 |
| JP6866409B2 JP6866409B2 (ja) | 2021-04-28 |
Family
ID=47178940
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539029A Active JP6154391B2 (ja) | 2011-10-28 | 2012-10-26 | 遺伝子改変された主要組織適合複合体マウス |
| JP2017109327A Active JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
| JP2019019707A Active JP6866409B2 (ja) | 2011-10-28 | 2019-02-06 | 遺伝子改変された主要組織適合複合体マウス |
| JP2020081774A Withdrawn JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539029A Active JP6154391B2 (ja) | 2011-10-28 | 2012-10-26 | 遺伝子改変された主要組織適合複合体マウス |
| JP2017109327A Active JP6574457B2 (ja) | 2011-10-28 | 2017-06-01 | 遺伝子改変された主要組織適合複合体マウス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081774A Withdrawn JP2020146041A (ja) | 2011-10-28 | 2020-05-07 | 遺伝子改変された主要組織適合複合体マウス |
Country Status (27)
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2818478T1 (sl) | 2011-10-28 | 2017-07-31 | Regeneron Pharmaceuticals, Inc. | Humanizirani il-6 in receptor il-6 |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| CA2902543A1 (en) * | 2013-03-11 | 2014-10-09 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules |
| HRP20231121T1 (hr) | 2013-09-23 | 2023-12-22 | Regeneron Pharmaceuticals, Inc. | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale |
| JP6492095B2 (ja) | 2013-10-15 | 2019-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化ｉｌ−１５動物 |
| US10278373B2 (en) | 2013-10-18 | 2019-05-07 | Taiho Pharmaceutical Co., Ltd. | HLA class I-expressing non-human animal |
| MY183188A (en) | 2013-11-19 | 2021-02-18 | Regeneron Pharma | Non-human animals having a humanized b-cell activating factor gene |
| US20150143559A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| RS60398B1 (sr) | 2014-04-08 | 2020-07-31 | Regeneron Pharma | Ne-humane životinje sa humanizovanim fc-gama receptorima |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| NO2785538T3 (cg-RX-API-DMAC10.html) | 2014-05-07 | 2018-08-04 | ||
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| BR112017010793A2 (pt) | 2014-11-24 | 2017-12-26 | Regeneron Pharma | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. |
| BR112017010490A2 (pt) | 2014-12-05 | 2018-04-03 | Regeneron Pharma | roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano. |
| ES2841353T3 (es) * | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| WO2016094679A1 (en) | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
| ES2950399T3 (es) * | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| CN108366548B (zh) | 2015-11-20 | 2021-10-08 | 瑞泽恩制药公司 | 具有人源化淋巴细胞活化基因3的非人动物 |
| CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
| CN109640644B (zh) | 2016-06-03 | 2021-10-26 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| CN109456942A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技（上海）有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
| DK3687287T5 (da) * | 2017-09-29 | 2024-08-26 | Regeneron Pharma | Gnavere, udtrykkende humaniseret c1q-kompleks |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| EP4534560A3 (en) | 2018-03-24 | 2025-06-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| IL277355B2 (en) | 2018-03-26 | 2025-01-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| CA3098040A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| JP2022527061A (ja) * | 2019-03-25 | 2022-05-30 | ゼノセラピューティクス インコーポレイテッド | ヒト化された、オーダーメイドされた、指定された病原体を含まない（非ヒト）ドナーから移植するための、個別化された細胞、組織、及び臓器、ならびにそれらに関連する方法及び製品 |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子１２遺伝子座を含む非ヒト動物 |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| EP4087392A4 (en) * | 2020-01-10 | 2024-02-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX |
| EP4262373A1 (en) | 2020-12-16 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| US20260114433A1 (en) * | 2020-12-16 | 2026-04-30 | Xenotherapeutics, Inc. | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human beta2-microglobulin within donor cells, tissues, or organs |
| CN116981357A (zh) | 2021-03-31 | 2023-10-31 | 瑞泽恩制药公司 | 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠 |
| US20250185635A1 (en) * | 2022-03-21 | 2025-06-12 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin and mhc loci |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| CA3265746A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF A HUMAN CELLULAR IMMUNE SYSTEM |
| EP4654982A1 (en) | 2023-01-27 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
| TW202520975A (zh) * | 2023-08-09 | 2025-06-01 | 英商劍橋企業有限公司 | 基因改造之囓齒動物及囓齒動物細胞以及其等用途 |
| KR20260074976A (ko) | 2023-09-19 | 2026-05-27 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 펩티드 및 이의 용도 |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| CN122438694A (zh) | 2023-12-19 | 2026-07-21 | 瑞泽恩制药公司 | Foxp3肽及其用途 |
| WO2025178991A1 (en) | 2024-02-21 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Splicing factor gene mutation-associated neoantigenic peptides and uses thereof |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2026006734A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development |
| WO2026006724A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Prame off-target peptides and uses thereof |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026096736A1 (en) | 2024-10-31 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Rodents expressing humanized polymeric immunoglobulin receptor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC ANIMALS HAVING TARGET LYMPHOCYTA TRANSDUCTION GENES. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| EP0910409A4 (en) | 1996-03-05 | 2003-03-19 | Scripps Research Inst | RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| DE69917541T2 (de) * | 1998-02-17 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | H2-o modifizierte transgene tiere |
| WO2001027291A1 (en) * | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| FR2827302B1 (fr) * | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| US7745690B2 (en) | 2004-03-09 | 2010-06-29 | Nagoya Industrial Science Research Institute | Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
| NZ547859A (en) * | 2006-06-09 | 2009-05-31 | Dec Int Nz Ltd | Treatment method and composition for mastitis |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| JP2010526066A (ja) * | 2007-04-23 | 2010-07-29 | シェーリング コーポレイション | 抗ｍｄｌ−１抗体 |
| EP2262898B1 (en) | 2008-03-07 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Es cell-derived mice from diploid host embryo injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP2153845A1 (en) * | 2008-08-13 | 2010-02-17 | Julius-Maximilians-Universität Würzburg | Endoglin peptides, vaccines and methods for preparing the same |
| DK3241435T3 (da) * | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| US9848587B2 (en) | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| SI2958937T1 (sl) | 2013-02-22 | 2018-12-31 | Regeneron Pharmaceuticals, Inc. | Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks |
| WO2014195159A1 (en) * | 2013-06-03 | 2014-12-11 | Theravectys | Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence |
| US10278373B2 (en) * | 2013-10-18 | 2019-05-07 | Taiho Pharmaceutical Co., Ltd. | HLA class I-expressing non-human animal |
| MX2017012829A (es) | 2015-04-06 | 2018-02-23 | Regeneron Pharma | Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. |
-
2012
- 2012-10-26 KR KR1020207002887A patent/KR102295746B1/ko active Active
- 2012-10-26 RS RS20190998A patent/RS59082B1/sr unknown
- 2012-10-26 CA CA3074400A patent/CA3074400C/en active Active
- 2012-10-26 HR HRP20171761TT patent/HRP20171761T1/hr unknown
- 2012-10-26 LT LTEP17184955.7T patent/LT3262932T/lt unknown
- 2012-10-26 MY MYPI2017703836A patent/MY178723A/en unknown
- 2012-10-26 MX MX2014004895A patent/MX355725B/es active IP Right Grant
- 2012-10-26 RS RS20171195A patent/RS56656B1/sr unknown
- 2012-10-26 PT PT127872554T patent/PT2770821T/pt unknown
- 2012-10-26 MY MYPI2014000784A patent/MY164836A/en unknown
- 2012-10-26 CA CA3311022A patent/CA3311022A1/en active Pending
- 2012-10-26 ES ES19167619T patent/ES2962287T3/es active Active
- 2012-10-26 EP EP17184955.7A patent/EP3262932B1/en active Active
- 2012-10-26 DK DK12787255.4T patent/DK2770821T3/da active
- 2012-10-26 CA CA2850387A patent/CA2850387A1/en active Pending
- 2012-10-26 EP EP12787255.4A patent/EP2770821B1/en active Active
- 2012-10-26 SG SG10201603188SA patent/SG10201603188SA/en unknown
- 2012-10-26 US US13/661,159 patent/US9615550B2/en active Active
- 2012-10-26 CN CN202110831383.7A patent/CN113564188B/zh active Active
- 2012-10-26 CN CN201280060540.8A patent/CN104039132B9/zh active Active
- 2012-10-26 SI SI201231136T patent/SI2770821T1/en unknown
- 2012-10-26 PL PL17184955T patent/PL3262932T3/pl unknown
- 2012-10-26 SM SM20170576T patent/SMT201700576T1/it unknown
- 2012-10-26 LT LTEP12787255.4T patent/LT2770821T/lt unknown
- 2012-10-26 KR KR1020147014476A patent/KR101921126B1/ko active Active
- 2012-10-26 ES ES12787255.4T patent/ES2651517T3/es active Active
- 2012-10-26 HU HUE12787255A patent/HUE035652T2/en unknown
- 2012-10-26 KR KR1020187033187A patent/KR102074145B1/ko active Active
- 2012-10-26 WO PCT/US2012/062042 patent/WO2013063346A1/en not_active Ceased
- 2012-10-26 CN CN201710347715.8A patent/CN107254480B/zh active Active
- 2012-10-26 EP EP19167619.6A patent/EP3563680B1/en active Active
- 2012-10-26 HU HUE17184955A patent/HUE045879T2/hu unknown
- 2012-10-26 JP JP2014539029A patent/JP6154391B2/ja active Active
- 2012-10-26 AU AU2012324016A patent/AU2012324016C1/en active Active
- 2012-10-26 BR BR112014009259-1A patent/BR112014009259A2/pt not_active Application Discontinuation
- 2012-10-26 MX MX2020010763A patent/MX391222B/es unknown
- 2012-10-26 ES ES17184955T patent/ES2741649T3/es active Active
- 2012-10-26 NZ NZ734532A patent/NZ734532A/en unknown
- 2012-10-26 PL PL12787255T patent/PL2770821T3/pl unknown
- 2012-10-26 SG SG11201400933VA patent/SG11201400933VA/en unknown
- 2012-10-26 EP EP23193595.8A patent/EP4311833A3/en active Pending
- 2012-10-26 PT PT17184955T patent/PT3262932T/pt unknown
- 2012-10-26 SI SI201231650T patent/SI3262932T1/sl unknown
- 2012-10-26 DK DK17184955.7T patent/DK3262932T3/da active
- 2012-10-26 SM SM20190478T patent/SMT201900478T1/it unknown
- 2012-10-26 MX MX2017013466A patent/MX376167B/es unknown
-
2014
- 2014-04-13 IL IL232097A patent/IL232097A/en active IP Right Grant
- 2014-04-25 ZA ZA2014/03085A patent/ZA201403085B/en unknown
-
2016
- 2016-04-27 AU AU2016202688A patent/AU2016202688B2/en active Active
-
2017
- 2017-02-22 US US15/439,828 patent/US10869466B2/en active Active
- 2017-04-30 IL IL252022A patent/IL252022A0/en active IP Right Grant
- 2017-06-01 JP JP2017109327A patent/JP6574457B2/ja active Active
- 2017-11-22 CY CY20171101223T patent/CY1119657T1/el unknown
- 2017-12-22 AU AU2017279797A patent/AU2017279797C1/en active Active
-
2018
- 2018-06-29 HK HK18108466.8A patent/HK1249712B/en unknown
- 2018-08-20 IL IL26123918A patent/IL261239B/en active IP Right Grant
-
2019
- 2019-02-06 JP JP2019019707A patent/JP6866409B2/ja active Active
- 2019-08-06 HR HRP20191420 patent/HRP20191420T1/hr unknown
- 2019-08-07 CY CY20191100840T patent/CY1121869T1/el unknown
-
2020
- 2020-05-07 JP JP2020081774A patent/JP2020146041A/ja not_active Withdrawn
- 2020-08-12 US US16/991,283 patent/US20200375160A1/en active Pending
-
2026
- 2026-03-04 US US19/556,620 patent/US20260182550A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ristevski | Making better transgenic models: conditional, temporal, and spatial approaches | |
| Liu et al. | Ablation of cDC2 development by triple mutations within the Zeb2 enhancer | |
| JP2017505127A5 (cg-RX-API-DMAC10.html) | ||
| AU2014253942B9 (en) | Targeted modification of rat genome | |
| Zhang et al. | Inactivation of the myogenic bHLH gene MRF4 results in up-regulation of myogenin and rib anomalies. | |
| Knapp et al. | Loss of myogenin in postnatal life leads to normal skeletal muscle but reduced body size | |
| Spear et al. | Transcriptional control in the mammalian liver: liver development, perinatal repression, and zonal gene regulation | |
| Miao et al. | Translation repression by maternal RNA binding protein Zar1 is essential for early oogenesis in zebrafish | |
| JP2017514496A5 (cg-RX-API-DMAC10.html) | ||
| RU2016123708A (ru) | Отличные от человека животные, содержащие гуманизированный ген фактора активации в-клеток | |
| HRP20202034T1 (hr) | Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274 | |
| WO2015077072A4 (en) | Non-human animals having a humanized a proliferation-inducing ligand gene | |
| JP2017514501A5 (cg-RX-API-DMAC10.html) | ||
| Lee et al. | Production of transgenic pig as an Alzheimer’s disease model using a multi-cistronic vector system | |
| JP2016510998A5 (cg-RX-API-DMAC10.html) | ||
| DK0620849T3 (da) | Transgene dyremodeller for Alzheimer's sygdom | |
| FR2814642A1 (fr) | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee | |
| Li et al. | A transgenic zebrafish model for monitoring xbp1 splicing and endoplasmic reticulum stress in vivo | |
| Oura et al. | KCTD19 and its associated protein ZFP541 are independently essential for meiosis in male mice | |
| JP2019506897A5 (cg-RX-API-DMAC10.html) | ||
| Hernández-Morán et al. | Degron tagging for rapid protein degradation in mice | |
| RU2676961C2 (ru) | Грызуны с условными мутантными аллелями acvr1 | |
| Koller et al. | Temporal and spatially controlled APP transgene expression using Cre-dependent alleles | |
| KR20210020018A (ko) | 진행성 골화성 섬유이형성증의 설치류 모델 | |
| Jin et al. | The alpha-fetoprotein enhancer region activates the albumin and alpha-fetoprotein promoters during liver development |